Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | N486_T491delinsK |
Impact List | indel |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF N486_T491delinsK results in a deletion of six amino acids in the protein kinase domain of the Braf protein from amino acids 486 to 491, combined with the insertion of a lysine (K) at the same site (UniProt.org). N486_A491delinsK confers a gain of function to Braf, as indicated by increased ERK activation and transformation of cultured cells (PMID: 30867592). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF N486_T491delinsK |
Transcript | NM_004333.6 |
gDNA | chr7:g.140778036_140778050del15 |
cDNA | c.1458_1472del15 |
Protein | p.N486_T491delinsK |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001378474.1 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140778036_140778050del15 | c.1458_1472del15 | p.N486_T491delinsK | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF N486_T491delinsK | lymphatic system cancer | predicted - sensitive | Cobimetinib | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Langerhans cell histiocytosis harboring BRAF N486_T491delinsK (PMID: 30867592; NCT01953926). | 30867592 |
BRAF N486_T491delinsK | Advanced Solid Tumor | predicted - sensitive | Cobimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cotellic (cobimetinib) inhibited viability of transformed cells expressing BRAF N486_T491delinsK in culture (PMID: 30867592). | 30867592 |